Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients

July 20, 2020 By The ASCO Post Staff

Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-dose cytarabine as a front-line treatment for older patients with acute myeloid leukemia, as well as for those who cannot tolerate intensive chemotherapy (Abstract S136).

Related Content